Clinical trial
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
NCT00006084 · Jonsson Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00006084 |
|---|---|
| Title | Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia |
| Official title | Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | lintuzumab |
| Start date | Feb 1, 2001 |
| First posted | Mar 25, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: